XBiotech (NASDAQ:XBIT) Stock Breaks Below 50-Day Moving Average – Here’s What Happened

Posted by Hanz Christensen on Sep 26th, 2026

Shares of XBiotech Inc. (NASDAQ:XBIT – Get Free Report) crossed below its 50 day moving average during trading on Thursday. The stock has a 50 day moving average of $2.25 and traded as low as $2.16. XBiotech shares last traded at $2.16, with a volume of 23,996 shares.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded XBiotech from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, September 14th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has an average rating of “Sell”.

Get Our Latest Stock Analysis on XBiotech

XBiotech Stock Up 0.5%

The stock has a market cap of $66.16 million, a PE ratio of -1.47 and a beta of 0.85. The company’s fifty day moving average is $2.25 and its 200 day moving average is $2.33.

XBiotech (NASDAQ:XBIT – Get Free Report) last released its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.25).

Institutional Trading of XBiotech

A number of institutional investors have recently added to or reduced their stakes in XBIT. Empowered Funds LLC acquired a new position in shares of XBiotech during the second quarter worth about $137,000. Bank of America Corp DE acquired a new stake in shares of XBiotech in the second quarter valued at about $55,000. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in XBiotech during the 2nd quarter worth $64,000. BlackRock Inc. purchased a new stake in XBiotech during the 2nd quarter worth $739,000. Finally, Bank of New York Mellon Corp acquired a new position in XBiotech in the 2nd quarter worth $91,000. 55.70% of the stock is owned by hedge funds and other institutional investors.

About XBiotech

(Get Free Report)

XBiotech Inc is a biotechnology company focused on developing therapies that target inflammation and other disease processes. The company’s technology platform is based on “True Human” monoclonal antibodies, which are derived from naturally occurring human antibodies rather than genetically engineered or animal-derived antibody sequences.

XBiotech’s research has included bermekimab, a fully human antibody designed to neutralize interleukin-1 alpha, an inflammatory protein associated with cancer, autoimmune conditions and other diseases.